Results 191 to 200 of about 10,268 (212)
Some of the next articles are maybe not open access.
Pediatric Drugs, 2003
Lansoprazole, a proton pump inhibitor, inactivates the H(+)/K(+)-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH. After 8-12 weeks' treatment with lansoprazole, all children (n = 27) with esophagitis at baseline were healed (confirmed by endoscopy) and 76% of 62 evaluable ...
openaire +2 more sources
Lansoprazole, a proton pump inhibitor, inactivates the H(+)/K(+)-ATPase pump in parietal cells, thereby suppressing basal and stimulated gastric acid secretion and increasing intragastric pH. After 8-12 weeks' treatment with lansoprazole, all children (n = 27) with esophagitis at baseline were healed (confirmed by endoscopy) and 76% of 62 evaluable ...
openaire +2 more sources
Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole
Alimentary Pharmacology & Therapeutics, 2004SummaryAim : To compare the pharmacokinetics and pharmacodynamics of lansoprazole 30 mg administered intravenously in 0.9% NaCl or in polyethylene glycol, or orally.Methods : Twenty‐nine subjects received lansoprazole orally on days 1–7 and intravenous lansoprazole in NaCl on days 8–14. Blood samples were collected on days 1, 7, 8 and 14. Fasting basal
J. S. Griffin +6 more
openaire +3 more sources
Crystal structure of lansoprazole sulfone
Journal of Structural Chemistry, 2007The structure of 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl} sulfonyl)-1H-1,3-benzimidazole, C16H14N3O3F3S, has been solved. The compound belongs to the monoclinic space group (P21/c) with cell parameters a = 8.8693(9) A, b = 23.369(2) A, c = 8.6141(8) A, β = 104.68(1)°, V = 1727.2(3) A3, Z = 4.
K. Ravikumar, G. Y. S. K. Swamy
openaire +2 more sources
Possible Lansoprazole-Induced Eosinophilic Syndrome
Annals of Pharmacotherapy, 1998OBJECTIVE: To report a case of myalgia with eosinophilia related to lansoprazole administration. CASE SUMMARY: A 50-year-old white woman developed severe myalgia 1 week after starting lansoprazole. During the treatment course, the patient was also found to have eosinophilia.
John G. Gums +2 more
openaire +2 more sources
Lansoprazole: A Proton Pump Inhibitor
Annals of Pharmacotherapy, 1996OBJECTIVE: To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
openaire +3 more sources
Pharmacokinetic Interaction Between Acetaminophen and Lansoprazole
Journal of Clinical Gastroenterology, 1999Because of its minimal gastric toxicity, acetaminophen is the analgesic of choice for patients with gastric acid-related disorders. Because proton pump inhibitors are widely used, concomitant prescription of acetaminophen and lansoprazole would be prevalent. This crossover study was conducted to investigate an acetaminophen-lansoprazole interaction. On
Iiku Enatsu +8 more
openaire +2 more sources
Lansoprazole for Maintenance of Remission of Erosive Oesophagitis
Drugs, 2002Gastro-oesophageal reflux disease, which is experienced daily by a significant proportion of individuals, may result in serious sequelae such as erosive oesophagitis. Short-term treatment with acid antisecretory therapy (a proton pump inhibitor or a histamine H(2) receptor antagonist) is highly effective in healing the erosive oesophagitis lesion ...
Bidan Huang +3 more
openaire +3 more sources
Delayed-Release Lansoprazole plus Naproxen
Drugs, 2004A combination package containing delayed-release capsules of the proton pump inhibitor lansoprazole (15 mg once daily) and tablets of the NSAID naproxen (375 or 500 mg twice daily) has been approved for reducing the risk of NSAID-associated gastric ulcers in NSAID-requiring patients with a documented history of gastric ulcer.
Keri Wellington, Monique P Curran
openaire +3 more sources
Lansoprazole: pharmacokinetics, pharmacodynamics and clinical uses
Expert Opinion on Pharmacotherapy, 2001Lansoprazole (Prevacid, TAP Pharmaceuticals, Inc.) is a substituted benzimidazole that inhibits gastric acid secretion. This agent is approved for the short-term treatment of erosive reflux oesophagitis, active gastric ulcer, active duodenal ulcer and the treatment of non-steroidal anti-inflammatory drug (NSAID)-induced gastric and duodenal ulcers.
openaire +3 more sources
Lansoprazole and Helicobacter pylori infection.
Clinical therapeutics, 1993Helicobacter pylori-associated gastritis is present in virtually all patients with duodenal ulcer (DU). Eradication of H pylori is associated with a highly significant decline in the recurrence rates of DU, indicating that treatments aimed at eradicating H pylori are mandatory in these patients.
PALLONE F +7 more
openaire +2 more sources